A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)

NCT02610062 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

23

Enrollment

INDUSTRY

Sponsor class

Stopped Business decision by sponsor

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: AGS67E

Sponsor

Astellas Pharma Global Development, Inc.